Furthermore, the characterized dependence of ER-negative breast cancer cells on NF-κB and the interaction of RANK-c with EGFR in breast cancer cell lines prompted us to further explore the possibility that RANK-c affects EGFR inhibition by known TKIs (erlotinib and gefitinib) [10,20]. The gene discussed is NFKB1; the disease is breast carcinoma.